Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with “standard” immunochemotherapy: A large retrospective study from 4 institutions-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with “standard” immunochemotherapy: A large retrospective study from 4 institutions

Published:2017-06-16 Issue:1 Volume:36 Page:84-92
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Gobba Stefania¹,Moccia Alden A.²^ORCID,Gulden-Sala Wiebke²,Conconi Annarita³⁴,Diem Stefan⁵,Cascione Luciano²⁶,Iacoboni Gloria²,Margiotta-Casaluci Gloria³,Aprile von Hohenstaufen Kathrin²,Stathis Anastasios²,Hitz Felicitas⁵,Pinotti Graziella¹,Gaidano Gianluca³,Zucca Emanuele²

Affiliation:

1. ASST Sette Laghi; Ospedale di Circolo e Fondazione Macchi; Varese Italy

2. Istituto Oncologico della Svizzera Italiana; Bellinzona Switzerland

3. SCDU Ematologia, Dipartimento di Medicina Traslazionale; Università degli Studi del Piemonte Orientale; Novara Italy

4. Unit of Hematology; Ospedale degli Infermi; Biella Italy

5. Klinik für Onkologie und Hämatologie; Kantonsspital St Gallen; St Gallen Switzerland

6. Lymphoma and Genomics Research Program; Institute of Oncology Research (IOR); Bellinzona Switzerland

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Reference44 articles.

1. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma;Vose;J Clin Oncol,1988

2. Management of elderly patients with hematological neoplasms;Mora;Ann Oncol,2007

3. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002

4. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study;Pfreundschuh;Lancet Oncol,May 2008

5. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte;Coiffier;Blood,2010

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diffuse Large B Cell Lymphoma in Patients 80 Years and Older: Worse Survival After Treatment Without Increased Relapse Rates;Clinical Lymphoma Myeloma and Leukemia;2021-11

2. Impact of therapeutic management and geriatric evaluation on patient of eighty years and older with diffuse large B‐cell lymphoma on survival: A systematic review;European Journal of Haematology;2021-09-21

3. Silencing Aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing β-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway;Bioengineered;2021-01-01

4. Doxorubicin and subsequent risk of cardiovascular diseases among survivors of diffuse large B-cell lymphoma in Hong Kong;Blood Advances;2020-10-21

5. Frontline treatments in extremely elderly patients with diffuse large B-cell lymphoma: a population-based study in Taiwan, 2010–2015;Immunity & Ageing;2020-06-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3